Lexicon Pharmaceuticals, Inc. (LXRX) 是一家上市公司 属于 医疗保健 板块，经营于 生物科技 行业. 公司总部位于 The Woodlands, TX, 美国. 现任CEO为 Michael S. Exton.
LXRX 拥有 IPO日期为 2000-04-07, 103 名全职员工, 在 NASDAQ Global Select, 市值为 $788.05M.
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.
